Planning and executing response-adaptive learn-phase clinical trials: 1. The process

Drug Information Journal

Volumn 43, Issue 6, 2009, Pages 713-723

  Fardipour, Parvin ^a   Littman, Gary ^b   Burns, Daniel D ^a   Dragalin, Vladimir ^a   Padmanabhan, S Krishna ^a   Parke, Tom ^c,d   Perevozskaya, Inna ^a   Relnold, Kathy ^c,d   Sharma, Amarnath ^a   Krams, Michael ^a  

^a PFIZER INC   (United States)

^b Applied Clinical Intelligence   (United States)

^c Tessella Inc ^*  (United Kingdom)

^d NONE

Author keywords

Adaptive design; Data monitoring committee report; Response adaptive allocation; Simulation report; Trial simulation

Indexed keywords

ADAPTATION; DATA ANALYSIS; DECISION MAKING; MONITORING; PLANNING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; REVIEW; SIMULATION; STATISTICAL ANALYSIS; VALIDITY;

EID: 72149125591     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150904300609     Document Type: Review

References (15)

1. Dragalin V. Designing, monitoring, and modifying an adaptive trial. Am Pharm Outsourcing. 2008;9(5):12-16.
2. Rosenberger WF, Lachin JM. The use of response- adaptive designs in clinical trials. Control Clin Trials. 1993;14:471-484. (Pubitemid 24003705)
3. Gaydos B, Krams M, Perevozskaya I, et al. Adaptive dose-response studies. Drug Inf J. 2006; 40:451-461.
4. Bornkamp B, Bretz F, Dmitrienko A, et al. White paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies: innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat. 2007;17:965-995.
5. Dragalin V, Fedorov V. Adaptive designs for dose- finding based on efficacy-toxicity response. J Stat Plan Infer. 2006;136:1800-1823. (Pubitemid 43193550)
6. Grieve AP, Krams M. ASTIN: A Bayesian adaptive dose-response trial in acute stroke. Clin Trials. 2005;2:340-351. (Pubitemid 41306277)
7. Quinlan JA, Krams M. Implementing adaptive designs: logistical and operational considerations. Drug Inf J. 2006;40:437-444. (Pubitemid 44721121)
8. Gallo P. Confidentiality and trial integrity issues for adaptive designs. Drug Inf J. 2006;40:445-449. (Pubitemid 44721122)
9. Enas G, Anderson K, Bedding A, et al. Global harmonization of standards for adaptive clinical trial designs. Reg Focus. 2008;13(8):8-17.
10. Chuang-Stein C, Bretz F, Komiyama O, Quinlan J. Interactions with regulatory agencies to enhance the understanding and acceptance of adaptive designs. Reg Focus. 2009;14(4):36-42.
11. Gaydos B, Anderson K, Berry DA, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J. 2009; 43:539-556.
12. Galbraith S, Marschner IC. Interim analysis of continuous long-term endpoints in clinical trials with longitudinal outcomes. Stat Med. 2003;22: 1787-1805. (Pubitemid 36603554)
13. B. Marschner IC, Becker SL. Interim monitoring of clinical trials based on long-term binary end- points. Stat Med. 2001;20:177-192.
14. Krams M, Sharma M, Dragalin V, et al. Adaptive approaches in clinical drug development: opportunities and challenges in design and implementation. Pharm Med. 2009;23(3):139-148.
15. Fardipour P, Littman G, Burns D, et al. Planning and executing response-adaptive learn-phase clinical trials: 2. Case studies. Drug Inf J. 2009; 43:725-734.